Akbarzadeh Marzieh, Eftekhari Mohammad Hassan, Dabbaghmanesh Mohammad Hossein, Hasanzadeh Jafar, Bakhshayeshkaram Marzieh
Department of Nutrition, School of Health and Nutrition, Shiraz University of Medical Sciences, Shiraz, Iran, e-mail:
Iran J Immunol. 2013 Sep;10(3):167-76.
Chronic low-grade systemic inflammation presented in Type 2 diabetes mellitus plays a major role in disease progression as well as development of micro- and macro-vascular complications of diabetes. Therefore, reducing inflammation can be beneficial in prevention of diabetes complications.
To investigate the association between insulin resistance and inflammatory markers, and assessing the effects of oral Calcitriol on inflammatory cytokines in type 2 diabetic patients.
In this double-blind randomized placebo-controlled trial, 70 participants with type-2 diabetes were randomly divided to two groups. One group received two capsules of Calcitriol (0.25 μg 1,25-dihydroxy cholecalciferol per each capsule) per day. The second group received placebo tablets. At the beginning of the study, we assessed insulin resistance and its relation to inflammatory profile. Serum high sensitive C-reactive protein (hs CRP), interleukin-6 and interleukin-18 were also measured at the beginning and the end of the 12-week supplementation trial.
Mean calcium, phosphorus and vitamin D concentrations in the study participants were 8.98 ± 0.79 mg/dL, 3.86 ± 0.50 mg/dL and 40.91 ± 30.9 ng/mL, respectively. IL-18 and hsCRP had significant positive associations with insulin resistance markers and negative associations with insulin sensitivity markers. At the end of the 12-week supplementation trial, no significant difference was seen in serum levels of hsCRP, IL-6 and IL-18 between the two groups, while these values were adjusted for baseline values.
Inflammation was associated with insulin resistance in diabetic patients. No anti-inflammatory effect of Calcitriol in terms of decreasing hsCRP, IL-6 and IL-18 detected.
2型糖尿病中存在的慢性低度全身炎症在疾病进展以及糖尿病微血管和大血管并发症的发生中起主要作用。因此，减轻炎症可能有助于预防糖尿病并发症。
研究胰岛素抵抗与炎症标志物之间的关联，并评估口服骨化三醇对2型糖尿病患者炎症细胞因子的影响。
在这项双盲随机安慰剂对照试验中，70名2型糖尿病参与者被随机分为两组。一组每天服用两粒骨化三醇胶囊（每粒含0.25μg 1,25 - 二羟胆钙化醇）。第二组服用安慰剂片。在研究开始时，我们评估了胰岛素抵抗及其与炎症指标的关系。在为期12周的补充试验开始和结束时，还测量了血清高敏C反应蛋白（hs CRP）、白细胞介素 - 6和白细胞介素 - 18。
研究参与者的平均钙、磷和维生素D浓度分别为8.98±0.79mg/dL、3.86±0.50mg/dL和40.91±30.9ng/mL。IL - 18和hsCRP与胰岛素抵抗标志物呈显著正相关，与胰岛素敏感性标志物呈负相关。在为期12周的补充试验结束时，两组之间hsCRP、IL - 6和IL - 18的血清水平无显著差异，而这些值已根据基线值进行了调整。
糖尿病患者的炎症与胰岛素抵抗相关。未检测到骨化三醇在降低hsCRP、IL - 6和IL - 18方面的抗炎作用。
